Most have treated ageing largely as a matter of pension reform.
Two patients were treated, aged 37 and 48 years.
To address these questions, we first treated aged mice (age at 18 23 months) with AT.
A total of 1,559 patients (91% female) have been treated, aged under 50 years.
Both rhTFAM treated groups acquired the platform faster and earlier than did the vehicle treated aged mice.
RhTFAM produced a 60% increase in the levels of the various subunits when compared to vehicle treated aged mice.
To test that possibility, we treated aged mice with rhTFAM in a manner similar to our prior study of treating young adult mice [ 21, 24].
The paradox of it is that while our culture increasingly treats growing old as a malady, women are increasingly pressured to treat aging as a pesky inconvenience best not acknowledged.
Even the idea of treating aging with hormones like testosterone, melatonin, and DHEA — currently being celebrated as the fountain of youth in one breathless magazine article after another — does not represent a dramatic departure from this way of thinking.
Furthermore, clinical trials to treat aging are impractical.
